vTv Therapeutics (VTVT) EBITDA Margin (2014 - 2026)

vTv Therapeutics (VTVT) has 11 years of EBITDA Margin data on file, last reported at 63.15% in Q1 2026.

• For the quarter ending Q1 2026, EBITDA Margin changed N/A year-over-year to 63.15%; the trailing twelve-month figure through Mar 2026 stood at 8.26% (up 14737998.0% YoY), and the FY2024 full-year result was 2377.58%, changed N/A from the prior year.
• EBITDA Margin rose to 63.15% in Q1 2026, from 28776.47% in the prior quarter.
• In the past five years, EBITDA Margin ranged from a high of 63.15% in Q1 2026 to a low of 70477.78% in Q4 2022.
• A 3-year average of 24137.05% and a median of 14669.59% in 2024 frame the typical range for EBITDA Margin.
• Peak annual rise in EBITDA Margin reached 5295556 bps in 2022, while the deepest fall reached 10959 bps in 2022.
• Tracing VTVT's EBITDA Margin over 3 years: stood at 70477.78% in 2022, then surged by 59 bps to 28776.47% in 2024, then surged by 100 bps to 63.15% in 2026.
• Business Quant data shows VTVT's EBITDA Margin at 63.15% in Q1 2026, 28776.47% in Q4 2024, and 562.7% in Q1 2024.